We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
- Authors
Mega, Jessica L; Simon, Tabassome; Collet, Jean-Philippe; Anderson, Jeffrey L; Antman, Elliott M; Bliden, Kevin; Cannon, Christopher P; Danchin, Nicolas; Giusti, Betti; Gurbel, Paul; Horne, Benjamin D; Hulot, Jean-Sebastian; Kastrati, Adnan; Montalescot, Gilles; Neumann, Franz-Josef; Shen, Lei; Sibbing, Dirk; Steg, P Gabriel; Trenk, Dietmar; Wiviott, Stephen D; Sabatine, Marc S
- Abstract
Clopidogrel, one of the most commonly prescribed medications, is a prodrug requiring CYP450 biotransformation. Data suggest its pharmacologic effect varies based on CYP2C19 genotype, but there is uncertainty regarding the clinical risk imparted by specific genotypes.
- Publication
JAMA, 2010, Vol 304, Issue 16, p1821
- ISSN
1538-3598
- Publication type
Journal Article
- DOI
10.1001/jama.2010.1543